Genentech To Submit Avastin sBLA For Vacaville Facility In First Half 2004
Executive Summary
Genentech will submit an sBLA for a back-up manufacturing site for the oncologic Avastin during the first half of 2004
You may also be interested in...
Genentech Avastin Launch Expected Within Three Weeks Of FDA Approval
Genentech and FDA are in negotiations over final labeling and Phase IV commitments.
Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon
Commercial supply for Genentech's vascular endothelial growth factor inhibitor Avastin could come from two manufacturing facilities, Chief Medical Officer Susan Hellmann, MD, said during an investor conference call July 9
Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says
Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease